stoxline Quote Chart Rank Option Currency Glossary
  
OraSure Technologies, Inc. (OSUR)
4.28  -0.14 (-3.17%)    06-17 16:00
Open: 4.37
High: 4.4
Volume: 1,497,868
  
Pre. Close: 4.42
Low: 4.125
Market Cap: 317(M)
Technical analysis
2024-06-17 5:25:35 PM
Short term     
Mid term     
Targets 6-month :  5.84 1-year :  6.48
Resists First :  5 Second :  5.55
Pivot price 4.61
Supports First :  4.11 Second :  3.42
MAs MA(5) :  4.4 MA(20) :  4.69
MA(100) :  6.01 MA(250) :  6.14
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  24.2 D(3) :  30
RSI RSI(14): 31.7
52-week High :  8.44 Low :  4.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OSUR ] has closed above bottom band by 1.5%. Bollinger Bands are 23.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.41 - 4.43 4.43 - 4.45
Low: 4.07 - 4.1 4.1 - 4.12
Close: 4.24 - 4.28 4.28 - 4.32
Company Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Headline News

Sat, 15 Jun 2024
OraSure Technologies' (NASDAQ:OSUR) investors will be pleased with their favorable 82% return over the last year - Yahoo Movies Canada

Tue, 11 Jun 2024
Campbell & CO Investment Adviser LLC Reduces Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) - Defense World

Wed, 22 May 2024
Assenagon Asset Management S.A. Sells 293,618 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) - MarketBeat

Fri, 17 May 2024
OraSure Technologies Stock Plan Expansion and Director Elections - TipRanks.com - TipRanks

Sat, 11 May 2024
Analysts Have Been Trimming Their OraSure Technologies, Inc. (NASDAQ:OSUR) Price Target After Its Latest Report - Yahoo Finance

Sat, 11 May 2024
OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 74 (M)
Shares Float 67 (M)
Held by Insiders 3.9 (%)
Held by Institutions 96.4 (%)
Shares Short 4,280 (K)
Shares Short P.Month 3,350 (K)
Stock Financials
EPS 0.3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.76
Profit Margin 7.5 %
Operating Margin -6.2 %
Return on Assets (ttm) 3 %
Return on Equity (ttm) 5.5 %
Qtrly Rev. Growth -65.1 %
Gross Profit (p.s.) 0
Sales Per Share 4.11
EBITDA (p.s.) 0.47
Qtrly Earnings Growth 0 %
Operating Cash Flow 142 (M)
Levered Free Cash Flow 151 (M)
Stock Valuations
PE Ratio 14.26
PEG Ratio -1.4
Price to Book value 0.74
Price to Sales 1.03
Price to Cash Flow 2.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android